Navigation Links
ZYBAN, The smoking cessation drug marked for its adverse reactions

GlaxoSmithKline's smoking cessation drug Zyban, which is being taken by over 5 million people world wide, is held responsilble for a raise in the suspected adverse reactions due to drug intake in UK.

Pharmacovigilance statistics of MCA has shown a raise of about 37% more adverse reactions so called "yellow cards" during the period of January to April 2001 compared to that of last years. MCA spokeswoman explained that the main factor responsible for such an increase in the "yellow cards" is the smoking cessation aid Zyban. However, from January to April 2001 Zyban "accounted for 32% of all yellow cards" she added.

Over 5000 adverse reactions including 40 deaths relating to Zyban has been reported.

As a result of this, the UK Committee on Safety of Medicines issued a statement to doctors and patients recommending change in the starting doses of Zyban and to use the drug only on compelling reasons for the patients at risk of seizures.

GSK spokesmam in response to this commented that Zyban is a prescription-only medicine that must be taken appropriately and not by patients with a history of seizures. He also added that the rate of seizures seen was consistent with the clinical trials experience.
'"/>




Page: 1

Related medicine news :

1. Vaccine to quit smoking?
2. A boost to quit smoking
3. Quitting smoking stops lung decline
4. Passive smoking affects respiratory system
5. Stop smoking and reduce weight
6. Teens listen to parents about smoking
7. Teen smoking declines
8. Cancer patients pursue smoking inspite of risks
9. A new herbal therapy to quit smoking
10. Watching television linked to smoking
11. Quit smoking after cancer diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... ... March 28, 2017 , ... City trips ... (IBT World Travel Trends Report). As travelers visit both urban destinations, they are ... and prolonged sun exposure. In response, the outdoor industry has blurred the lines ...
(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, LLC, ... of Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to ... developed in association with efforts by the American College of Surgeons, U.S. Department ...
(Date:3/28/2017)... Calif. (PRWEB) , ... March 28, 2017 , ... ... its leading physicians, Paul Yost, will begin serving as new board chair for ... this month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... In ... Self-Funding Success website has recently developed and published an informational resource that addresses ... created based on common inquiries the site’s team of third party administrator (TPA) ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric surgeon and well-known ... to offer the recently FDA-approved Obalon Balloon System to his patients. The Obalon ... Surgical’s already comprehensive list of weight-loss services. Dr. Liu is proud to ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... 2017  Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. ... of directors: Christopher Gabrieli ... serve as chairman of the board of Akcea Therapeutics. ... of Forest Laboratories. Sandford D. Smith ... "We are excited to announce this expansion to ...
(Date:3/28/2017)... , March 28, 2017 ... expected to reach a value of USD 4.5 billion ... View Research, Inc. Proper closure of injured tissues post ... and function. Postoperative leakages occur in 3% to 15% ... They are responsible for one third of postoperative deaths ...
(Date:3/27/2017)... , March 27, 2017 The National ... health and data analytics company, signed a Memorandum ... improving healthcare delivery in the region. ... Global Health Research and Technology (BIGHEART) at NUS ... several topics related to healthcare IT and medical ...
Breaking Medicine Technology: